BioSpace News Archive

NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology company accelerating the genetic revolution using a new class of synthetic medicines to drug the genome, today announced execution of a binding agreement to acquire infrastructure, programs and intellectual property for several peptide-nucleic acid (PNA) scaffolds from Vera Therapeutics, formerly known as TruCode Gene Repair, Inc.

OPKO Health, Inc. (NASDAQ: OPK) announced today that its partner, Pfizer Japan Inc., submitted a New Drug Application (NDA) to the Ministry of Health, Labour, and Welfare in Japan for somatrogon, a long-acting recombinant human growth hormone that is intended to be administered once-weekly for the treatment of pediatric patients with growth hormone deficiency (GHD).

Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced it will host a Key Opinion Leader (KOL) webinar and provide a corporate update on Thursday, February 4, 2021, at 12:00 PM Eastern Time

A Quebec research team has discovered two early plasma markers to detect Alzheimer’s disease five years before its onset.

Sai Life Sciences, one of India’s fastest growing Contract Research, Development & Manufacturing Organizations, announced plans to double its headcount and expand its suite of technical capabilities at its Manchester site, a centre of excellence for API process and analytical development serving an expanding list of global clients.

Novamind’s subsidiary Cedar Psychiatry has administered over 5,000 ketamine treatments and over 2,000 Spravato™ treatments

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the fourth quarter and year ending December 31, 2020 on Thursday, February 11, 2021, before the U.S. financial markets open.

Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, announced today announced the pricing of an underwritten public offering of units for gross proceeds of approximately $9.6 million prior to deducting underwriting discounts and commissions and offering expenses payable by Helius.

CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that fourth quarter and full year 2020 financial results will be released on Thursday, February 11, 2021 after the market closes.

-BrainStorm-Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, announced today that the Company will hold a conference call to update shareholders on financial results for the fourth quarter and year ended December 31, 2020